Latest News - Psoriasis

Wednesday, November 22, 2017 | PracticalDermatology.com, Product Launches and Updates, Research and Publications, Janssen, Pfizer

New Analysis Provides Reassurance on Biosimilar Safety

And they’re … safe. Biosimilars, which have been available in the European Union since 2006, show no substantial differences in the reporting of safety information than their originato…

Read the full story

Friday, November 17, 2017 | PracticalDermatology.com, Amgen

Amgen Launches The Enbrel Mini Single-Dose Prefilled Cartridge With AutoTouch Reusable Autoinjector

Amgen's Enbrel Mini with AutoTouch is now available in the United States. Awarded the Arthritis Foundation Ease of Use Commendation, this new and innovative delivery system provides an additional …

Read the full story

Thursday, November 16, 2017 | PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, Research and Publications

Parent-supplied Photos May Allow Pediatric Derms to Make Virtual Diagnoses

Parent-supplied photos taken via smartphone cameras can allow pediatric dermatologists to make a diagnosis without an office visit in many cases, new research shows. This finding, which appear…

Read the full story

Wednesday, November 15, 2017 | PracticalDermatology.com, Research and Publications

Psoriasis Severity Linked to Diabetes Risk

Psoriasis patients are more likely to develop Type 2 diabetes than their psoriasis-free counterparts, and this risk increases dramatically based on the severity of the disease, according to researcher…

Read the full story

Tuesday, November 14, 2017 | Personnel/Company News, PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, Valeant NJ

Ortho Dermatologics Announces Aspire Higher Scholarship Honorees

Ortho Dermatologics announced the nine recipients of the Aspire Higher Scholarship program, which honors the achievements of applicants or current attendees of an accredited, nonprofit, two- or four-y…

Read the full story

Wednesday, November 08, 2017 | Phase 3/4 Trials, PracticalDermatology.com

Long-Term Use of Lilly's Taltz Shows Efficacy Improvements in PsA for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors

Patients with active psoriatic arthritis (PsA) treated with Taltz (ixekizumab), who were previously intolerant or had inadequate responses to TNF inhibitors, showed improvements in the signs and sympt…

Read the full story

Friday, November 03, 2017 | PracticalDermatology.com, Research and Publications

Study: PsO, RA Patients Prescribed Similar Drugs, But PsO Patients Face Higher Liver Disease Risk

Compared to controls, patients with psoriasis (PsO) are at higher risk for serious liver disease than patients with rheumatoid arthritis, reports a in the Journal of Investigative Dermatology fro…

Read the full story

Thursday, November 02, 2017 | FDA Approval/Clearance, PracticalDermatology.com, Product Launches and Updates, Valeant NJ

FDA Accepts Ortho Dermatologic’s NDA for Novel Plaque Psoriasis Treatment, IDP-118

The US Food and Drug Administration has accepted Ortho Dermatologic's New Drug Application (NDA) for IDP-118 (halobetasol propionate and tazarotene) lotion, an investigational topical treatme…

Read the full story

Friday, October 27, 2017 | Phase 3/4 Trials, PracticalDermatology.com, Research and Publications, AbbVie

Abbvie's Risankizumab Performs Well in Three Phase Three Psoriasis Studies

Top-line results from three pivotal Phase 3 clinical trials show that  risankizumab, an investigational interleukin-23 (IL-23) inhibitor, met the co-primary endpoints of at least a 90 percent imp…

Read the full story

Monday, October 23, 2017 | FDA Approval/Clearance, PracticalDermatology.com, Product Launches and Updates

FDA Approves Janssen’s Golimumab for PsA, AS

  The FDA approved Janssen’s SIMPONI ARIA (golimumab) for the treatment of adults with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS). Simponi is the only…

Read the full story

Monday, October 16, 2017 | PracticalDermatology.com, Research and Publications

Ortho Dermatologics: Long-term Efficacy Data for Siliq

Siliq™ (brodalumab) injection provided sustained high levels of skin clearance (PASI 100) over more than two years in patients with moderate-to-severe psoriasis, according to data presented at t…

Read the full story

Friday, October 13, 2017 | FDA Approval/Clearance, PracticalDermatology.com, Product Launches and Updates

FDA Approves Stelara for Treatment of Adolescents with Moderate To Severe Plaque Psoriasis

The FDA approved an expanded indication for Janssen Biotech, Inc.'s Stelara (ustekinumab) for the treatment of adolescents (12 years of age or older) with moderate to severe plaque psoriasis who a…

Read the full story

Tuesday, October 03, 2017 | PracticalDermatology.com, Psoriasis

Penn Derm Awarded $8.6M to Study Home Versus In-Office Phototherapy Treatment for Psoriasis

A research team at the University of Pennsylvania will receive $8.6 million to study the effectiveness of home-based phototherapy treatments for psoriasis compared to treatments that require a visit t…

Read the full story

Wednesday, September 20, 2017 | Phase 3/4 Trials, PracticalDermatology.com, Research and Publications

Two-Year Data: TREMFYA™ (guselkumab) Achieves Consistent Rates of Skin Clearance in Moderate to Severe Plaque Psoriasis

New longer-term data from the open-label extension of the VOYAGE 1 trial demonstrate consistent rates of skin clearance with TREMFYA™ treatment through week 100 among patients with moderate…

Read the full story

Wednesday, September 13, 2017 | Phase 3/4 Trials, PracticalDermatology.com, Novartis

Five-Year Data Show Sustained Efficacy, Safety for Cosentyx

Novartis’ IL-17 blocker Cosentyx® (secukinumab) maintains PASI 90 and PASI 100 response rates at five years in patients with moderate to severe plaque psoriasis, according to new Phase …

Read the full story
Load More